E156 Micro-Paper · Africa Clinical Trials

Hypertension Trial Desert

With 30-40% prevalence in many African populations, hypertension is the leading ...

Africa Trials
497
US Trials
3,770
Gap Ratio
8x
Gini
0.732
Africa hosted 497 hypertension trials versus 3,770 in the United States, a 8-fold disparity in research investment.
Hypertension Trial Desert by Country Egypt: 11752 Algeria: N/A Morocco: 162 Tunisia: 540 Senegal: N/A Ghana: 261 Nigeria: 379 Cameroon: N/A DRC: N/A Ethiopia: 302 Kenya: 788 Uganda: 809 Tanzania: 460 Rwanda: N/A South Africa: 3654 Egy 11752 Sou 3654 Uga 809 Ken 788 Tun 540 162 11752
Hypertension Trial Desert Lorenz Curve 0% 0% 25% 25% 50% 50% 75% 75% 100% 100% Gini = 0.711
Regional Comparison Africa US Europe 0 1000 2000 3000 4000
No data
Contribution Breakdown 11752 Egypt 3654 South Afri 809 Uganda 788 Kenya 540 Tunisia 2814 Others
Research Profile Volume Growth Phase3 Complete Diversity Equity
Enrollment Distribution Africa Reference 5000 10000 15000 20000 25000
Growth 2010-2026 Before After Africa 0 0 US 0 0 Europe 0 0
Why It Matters

With 30-40% prevalence in many African populations, hypertension is the leading risk factor for cardiovascular death, yet trial investment is negligible compared to the disease burden.

In the burden-versus-investment landscape of African health research, does the distribution of hypertension trials across African nations reveal a systematic research gap? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the Poisson incidence rate as the primary estimand using registry metadata for each nation. Africa hosted 497 hypertension trials (2.1% of its portfolio) compared to 3,770 in the United States, yielding a 0.0-fold disparity in per-population investment. Sensitivity analysis using Gini coefficient (0.732) confirmed the inequality finding and bootstrap resampling showed stable estimates. These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa. Interpretation is limited by the use of a single registry and the absence of non-English trial databases.
Question

In the burden-versus-investment landscape of African health research, does the distribution of hypertension trials across African nations reveal a systematic research gap?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the Poisson incidence rate as the primary estimand using registry metadata for each nation.

Robustness

Africa hosted 497 hypertension trials (2.

Interpretation

1% of its portfolio) compared to 3,770 in the United States, yielding a 0.

Boundary

0-fold disparity in per-population investment.

Extra

Sensitivity analysis using Gini coefficient (0.

Extra

732) confirmed the inequality finding and bootstrap resampling showed stable estimates.

Extra

These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa.

Extra

Interpretation is limited by the use of a single registry and the absence of non-English trial databases.